Premium
Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand
Author(s) -
Duffy Eamon,
Arroll Nicola,
Beasley Richard,
Hills Thomas
Publication year - 2021
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41643
Subject(s) - medicine , hydroxychloroquine , adverse effect , randomized controlled trial , medical prescription , clinical trial , intensive care medicine , covid-19 , pharmacology , disease , infectious disease (medical specialty)
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom